N-[1-[(3,5-dimethylisoxazol-4-yl)methyl]pyrazol-4-yl]-2-methoxy-pyridine-3-carboxamide

ID: ALA4579065

PubChem CID: 155565412

Max Phase: Preclinical

Molecular Formula: C16H17N5O3

Molecular Weight: 327.34

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  COc1ncccc1C(=O)Nc1cnn(Cc2c(C)noc2C)c1

Standard InChI:  InChI=1S/C16H17N5O3/c1-10-14(11(2)24-20-10)9-21-8-12(7-18-21)19-15(22)13-5-4-6-17-16(13)23-3/h4-8H,9H2,1-3H3,(H,19,22)

Standard InChI Key:  VIIZBANUYOKXOO-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 24 26  0  0  0  0  0  0  0  0999 V2000
   31.6352   -3.4504    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.4565   -3.4504    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.7150   -2.6696    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.0479   -2.1874    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   31.3850   -2.6696    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   31.1540   -4.1150    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.4967   -2.4181    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.9402   -4.1162    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.7571   -4.0317    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   34.3065   -4.6437    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.0575   -4.3081    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.9689   -3.4911    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.1657   -3.3204    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   35.7648   -4.7216    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   36.4771   -4.3098    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.1884   -4.7233    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.4780   -3.4884    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   37.1826   -5.5439    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.8932   -5.9533    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   38.6064   -5.5454    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   38.6048   -4.7199    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.8937   -4.3101    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.4737   -5.9504    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   36.4712   -6.7675    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  1  1  0
  1  6  1  0
  3  7  1  0
  2  8  1  0
  8  9  1  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13  9  1  0
 11 14  1  0
 14 15  1  0
 15 16  1  0
 15 17  2  0
 16 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 16  1  0
 18 23  1  0
 23 24  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4579065

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 327.34

Molecular Weight (Monoisotopic): 327.1331

AlogP: 2.19

#Rotatable Bonds: 5

Polar Surface Area: 95.07

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 2.64

CX LogP: 1.13

CX LogD: 1.13

Aromatic Rings: 3

Heavy Atoms: 24

QED Weighted: 0.77

Np Likeness Score: -2.75

References

1. Fotsing JR, Darmohusodo V, Patron AP, Ching BW, Brady T, Arellano M, Chen Q, Davis TJ, Liu H, Servant G, Zhang L, Williams M, Saganich M, Ditschun T, Tachdjian C, Karanewsky DS..  (2020)  Discovery and Development of S6821 and S7958 as Potent TAS2R8 Antagonists.,  63  (9): [PMID:32330040] [10.1021/acs.jmedchem.0c00388]

Source

Source(1):

• Scientific Literature